The Dunedin Study's observational cohort of 1037 participants tracked since birth reveals pTau181 elevations at age 45 correlating with subjective memory complaints, an observational design with no randomization and potential selection bias from New Zealand's relatively homogeneous population. This contrasts with RCTs like the FINGER trial (n=1260, multi-domain lifestyle intervention showing 25% cognitive benefit in at-risk older adults, no major conflicts disclosed beyond industry partnerships for supplements). The MedicalXpress coverage underplays how pTau181's midlife rise—absent MRI or objective cognitive links—may mark a pre-pathological phase missed by late-stage biomarker studies in cohorts over 65. Synthesizing these, early detection could pivot Alzheimer's from symptomatic management to scalable prevention, aligning with modifiable risks like hypertension addressed in observational data from the Lancet Commission on dementia prevention. Limitations include Dunedin's modest sample for biomarker subgroups and lack of longitudinal pTau181 trajectories; conflicts appear minimal as academic-led. This underscores midlife as critical for intervention before irreversible cascades.